Different mechanisms of fibrinolysis impairment among dyslipidemic subjects

International Journal of Clinical Pharmacology Research

Volumn 21, Issue 3-4, 2001, Pages 147-155

  Puccetti, L ^a   Pasqui, A L ^a   Pastorelli, M ^a   Bova, G ^a   Cercignani, M ^a   Palazzuoli, A ^a   Auteri, A ^a   Bruni, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; PARAMETER; PROTEIN SYNTHESIS; VEIN OCCLUSION;

ADULT; ANALYSIS OF VARIANCE; FEMALE; FIBRINOLYSIS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIAS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; STATISTICS, NONPARAMETRIC;

EID: 0035560478     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease
2. Prospective study of endogenous tissue plasminogen activator and risk of stroke
3. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris
4. The fibrinolytic system in diabetes mellitus
5. ECAT angina pectoris study: Baseline associations of haemostatic factors with the extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography
6. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin
7. Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol
8. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis
9. Plasma tissue plasminogen activator inhibitor levels in coronary disease: Correlation with age and serum triglyceride concentration
10. Hypertriglyceridemia and regulation of fibrinolytic activity
11. Fibronolysis in hypertrigliceridaemic subjects in response to venous occlusion
12. Activation of coagulation but normal fibrinolysis in patients with type IIa hyperlipoproteinemia
13. Hypertriglyceridemia but not hypercholesterolemia is associated with the alterations of the fibfinolytic system
14. Relationship between prothrombin activation fragment F1+2 and serum cholesterol
15. Platelet-dependent thrombin generation in patients with hyperlipidemia
16. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia
17. Activation of fibrinolysis by apolipoproteins of high density Iipoproteins in man
18. Purification and characterization of TAFI, a activable fibrinolysis inhibitor
19. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascade through the thrombin-thrombomodulin complex
20. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis
21. Plasma pro-carboxypeptidase U in men with symptomatic coronary artery disease
22. Circulating adhesion molecules in disease
23. Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers
24. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation
25. Fibrinogen plasma levels as marker of thrombin activation: New insights on the role of fibrinogen as a cardiovascular risk factor
26. Hyperhomocystinemia, atherosclerosis and thrombosis
27. Lipoprotein(a): An interloper into the fibrinolytic system?
28. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
29. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
30. Assay of procarboxypeptidase U, a novel determinant of the fibrinoytic cascade, in human plasma
31. Pathophysiology of fibrinolysis
32. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia
33. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
34. Antiatherothrombotic properties of statins. Implication for cardiovascular event reduction
35. The anti-thrombotic effects of statins
36. Gemfibrozil treatment of combined hyperlipoproteinemia
37. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy
38. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1